tbuckley/cabot-search huggingface dataset:
The Ruminant Telomere-to-Telomere (RT2T) Consortium
Authors: Theodore S. Kalbfleisch, Stephanie D. McKay, Brenda M. Murdoch, David L. Adelson, Diego Almansa-Villa, Gabrielle Becker, Linda M. Beckett, María José Benítez-Galeano, Fernando Biase, Theresa Casey, Edward Chuong, Emily Clark, Shannon Clarke, Noelle Cockett, Christine Couldrey, Brian W. Davis, Christine G. Elsik, Thomas Faraut, Yahui Gao, Carine Genet, Patrick Grady, Jonathan Green, Richard Green, Dailu Guan, Darren Hagen, Gabrielle A. Hartley, Mike Heaton, Savannah J. Hoyt, Wen Huang, Erich Jarvis, Jenna Kalleberg, Hasan Khatib, Klaus-Peter Koepfi, James Koltes, Sergey Koren, Christa Kuehn, Tosso Leeb, Alexander Leonard, George E. Liu, Wai Yee Low, Hunter McConnell, Kathryn McRae, Karen Miga, Michelle Mousel, Holly Neibergs, Temitayo Olagunju, Matt Pennell, Bruna Petry, Mirjam Pewsner, Adam M. Phillippy, Brandon D. Pickett, Paulene Pineda, Tamara Potapova, Satyanarayana Rachagani, Arang Rhie, Monique Rijnkels, Annie Robic, Nelida Rodriguez Osorio, Yana Safonova, Gustavo Schettini, Robert D. Schnabel, Nagabhishek Sirpu Natesh, Morgan Stegemiller, Jessica Storer, Paul Stothard, Caleb Stull, Gwenola Tosser-Klopp, Germán M. Traglia, Christopher K. Tuggle, Curtis P. Van Tassell, Corey Watson, Rosemarie Weikard, Klaus Wimmers, Shangqian Xie, Liu Yang, Timothy P. L. Smith, Rachel J. O’Neill, Benjamin D. Rosen
Journal: Nature Genetics (2024)
Human Chorionic Membrane‐derived Tunable Hydrogels for Vascular Tissue Engineering Strategies
Authors: Elisa A.G. Martins, Inês A. Deus, Maria C. Gomes, Ana S. Silva, João F. Mano, Catarina A. Custódio
Journal: Advanced Healthcare Materials (2024)

Abstract One of the foremost targets in the advancement of biomaterials to engineer vascularized tissues is not only to replicate the composition of the intended tissue but also to create thicker structures incorporating a vascular network for adequate nutrients and oxygen supply. For the first time, to the best of current knowledge, a clinically relevant biomaterial is developed, demonstrating that hydrogels made from the human decellularized extracellular matrix can exhibit robust mechanical properties (in the kPa range) and angiogenic capabilities simultaneously. These properties enable the culture and organization of human umbilical vein endothelial cells into tubular structures, maintaining their integrity for 14 days in vitro without the need for additional polymers or angiogenesis‐related factors. This is achieved by repurposing the placenta chorionic membrane (CM), a medical waste with an exceptional biochemical composition, into a valuable resource for bioengineering purposes. After decellularization, the CM underwent chemical modification with methacryloyl groups, giving rise to methacrylated CM (CMMA). CMMA preserved key proteins, as well as glycosaminoglycans. The resulting hydrogels rapidly photopolymerize and have enhanced strength and customizable mechanical properties. Furthermore, they demonstrate angio‐vasculogenic competence in vitro and in vivo, holding significant promise as a humanized platform for the engineering of vascularized tissues.
Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance
Authors: Venu Thatikonda, Hengyu Lyu, Sabine Jurado, Kaja Kostyrko, Christopher A. Bristow, Christoph Albrecht, Donat Alpar, Heribert Arnhof, Oliver Bergner, Karin Bosch, Ningping Feng, Sisi Gao, Daniel Gerlach, Michael Gmachl, Melanie Hinkel, Simone Lieb, Astrid Jeschko, Annette A. Machado, Thomas Madensky, Ethan D. Marszalek, Mikhila Mahendra, Gabriella Melo-Zainzinger, Jessica M. Molkentine, Philipp A. Jaeger, David H. Peng, Robyn L. Schenk, Alexey Sorokin, Sandra Strauss, Francesca Trapani, Scott Kopetz, Christopher P. Vellano, Mark Petronczki, Norbert Kraut, Timothy P. Heffernan, Joseph R. Marszalek, Mark Pearson, Irene C. Waizenegger, Marco H. Hofmann
Journal: Nature Cancer (2024)

Abstract Combination approaches are needed to strengthen and extend the clinical response to KRAS G12C inhibitors (KRAS G12C i). Here, we assessed the antitumor responses of KRAS G12C mutant lung and colorectal cancer models to combination treatment with a SOS1 inhibitor (SOS1i), BI-3406, plus the KRAS G12C inhibitor, adagrasib. We found that responses to BI-3406 plus adagrasib were stronger than to adagrasib alone, comparable to adagrasib with SHP2 (SHP2i) or EGFR inhibitors and correlated with stronger suppression of RAS-MAPK signaling. BI-3406 plus adagrasib treatment also delayed the emergence of acquired resistance and elicited antitumor responses from adagrasib-resistant models. Resistance to KRAS G12C i seemed to be driven by upregulation of MRAS activity, which both SOS1i and SHP2i were found to potently inhibit. Knockdown of SHOC2 , a MRAS complex partner, partially restored response to KRAS G12C i treatment. These results suggest KRAS G12C plus SOS1i to be a promising strategy for treating both KRAS G12C i naive and relapsed KRAS G12C -mutant tumors.
The effects of single and multiple resistance mechanisms on bacterial response to meropenem
Authors: Dominika T. Fuhs, Sara Cortés-Lara, Jessica R. Tait, Kate E. Rogers, Carla López-Causapé, Wee Leng Lee, David M. Shackleford, Roger L. Nation, Antonio Oliver, Cornelia B. Landersdorfer
Journal: Clinical Microbiology and Infection (2024)

ObjectivesMeropenem is commonly used against Pseudomonas aeruginosa. Traditionally, the time unbound antibiotic concentration exceeds the MIC (fT>MIC) is used to select carbapenem regimens. We aimed to characterize the effects of different baseline resistance mechanisms on bacterial killing and resistance emergence; evaluate whether fT>MIC can predict these effects; and, develop a novel Quantitative and Systems Pharmacology (QSP) model to describe the effects of baseline resistance mechanisms on the time-course of bacterial response.MethodsSeven isogenic P. aeruginosa strains with a range of resistance mechanisms and MICs were used in 10-day hollow-fiber infection model studies. Meropenem pharmacokinetic profiles were simulated for various regimens (t1/2,meropenem = 1.5 h). All viable counts on drug-free, 3 × MIC, and 5 × MIC meropenem-containing agar across all strains, five regimens, and control (n = 90 profiles) were simultaneously subjected to QSP modeling. Whole genome sequencing was completed for total population samples and emergent resistant colonies at 239 h.ResultsRegimens achieving ≥98%fT>1 × MIC suppressed resistance emergence of the mexR knockout strain. Even 100%fT>5 × MIC failed to achieve this against the strain with OprD loss and the ampD and mexR double-knockout strain. Baseline resistance mechanisms affected bacterial outcomes, even for strains with the same MIC. Genomic analysis revealed that pre-existing resistant subpopulations drove resistance emergence. During meropenem exposure, mutations in mexR were selected in strains with baseline oprD mutations, and vice versa, confirming these as major mechanisms of resistance emergence. Secondary mutations occurred in lysS or argS, coding for lysyl and arginyl tRNA synthetases, respectively.DiscussionThe QSP model well-characterized all bacterial outcomes of the seven strains simultaneously, which fT>MIC could not.
Long-Term Incidence of Bradycardia and Pacemaker Implantations Among Cross-Country Skiers: A Cohort Study
Authors: Niclas Svedberg, Johan Sundström, Stefan James, Ulf Hållmarker, Kristina Hambraeus, Kasper Andersen
Journal: Circulation (2024)

BACKGROUND: Bradycardia is more common among well-trained athletes than in the general population, but the association with pacemaker implantations is less known. We investigated associations of endurance training with incidence of bradycardia and pacemaker implantations, including sex differences and long-term outcome, in a cohort of endurance trained individuals. METHODS: All Swedish skiers who completed &gt;1 race in the cross-country skiing event Vasaloppet between 1989 and 2011 (n=209 108) and a sample of 532 290 nonskiers were followed until first event of bradycardia, pacemaker implantation, or death, depending on end point. The Swedish National Patient Register was used to obtain diagnoses. Cox regression was used to investigate associations of number of completed races and finishing time in Vasaloppet with incidence of bradycardia and pacemaker implantations. In addition, Cox regression was used to investigate associations of pacemaker implantations with death in skiers and nonskiers. RESULTS: Male skiers had a higher incidence of bradycardia (adjusted hazard ratio [aHR], 1.19 [95% CI, 1.05–1.34]) and pacemaker implantations (aHR, 1.17 [95% CI, 1.04–1.31]) compared with male nonskiers. Those who completed the most races and had the best performances exhibited the highest incidence. For female skiers in Vasaloppet, the incidence of bradycardia (aHR, 0.98 [95% CI, 0.75–1.30]) and pacemaker implantations (aHR, 0.98 [95% CI, 0.75–1.29]) was not different from that of female nonskiers. The indication for pacemaker differed between skiers and nonskiers, with sick sinus syndrome more common in the former and third-degree atrioventricular block in the latter. Skiers had lower overall mortality rates than nonskiers (aHR, 0.16 [95% CI, 0.15–0.17]). There were no differences in mortality rates by pacemaker status among skiers. CONCLUSIONS: In this study, male endurance skiers had a higher incidence of bradycardia and pacemaker implantations compared with nonskiers, a pattern not seen in women. Among male skiers, those who completed the most races and had the fastest finishing times had the highest incidence of bradycardia and pacemaker implantations. Within each group, mortality rates did not differ in relation to pacemaker status. These findings suggest that bradycardia associated with training leads to a higher risk for pacemaker implantation without a detrimental effect on mortality risk.
Transfusion independence after lenalidomide discontinuation in patients with del(5q) myelodysplastic neoplasm: a HARMONY Alliance study
Authors: Elena Crisà, Elvira Mora, Ulrich Germing, Cecile Bally, Maria Diez Campelo, Mikko Myllymäki, Martin Jädersten, Rami Komrokji, Uwe Platzbecker, Detlef Haase, Wolf-Karsten Hofmann, Najla H. Al Ali, Daniela Barraco, Juan José Bargay, Teresa Bernal, Felix López Cadenas, Anna Calvisi, Isabella Capodanno, Marco Cerrano, Rosanna Ciancia, Monica Crugnola, Andrea Kündgen, Carlo Finelli, Claudio Fozza, Chiara Frairia, Ebeling Freja, Christina Ganster, Anne Sophie Kubasch, Maria Jose Jimenez, Roberto Latagliata, Francisca Hernandez Mohedo, Antonieta Molero, Miriam Vara Pampliega, Clara Aparicio Perez, Giuseppe Pietrantuono, Antonella Poloni, Helena Pomares, Valle Recasens, Axel Rüfer, Alessio Signori, Eva Hellstrom-Lindberg, Pierre Fenaux, Guillermo Sanz, Valeria Santini
Journal: Leukemia (2024)
Contemporary Outcomes and Trends for the Transseptal Mitral Valve-in-Valve Procedure Using Balloon Expandable Transcatheter Valves in the United States
Authors: Kashish Goel, Raj Makkar, Amar Krishnaswamy, Samir R. Kapadia, Susheel K. Kodali, Ashish Shah, Colin M. Barker, Ke Xu, Abhijeet Dhoble, Pradeep Yadav, Charanjit S. Rihal, Amr E. Abbas, Mayra Guerrero, Brian K. Whisenant
Journal: Circulation (2024)

Previous transcatheter valve therapy registry analyses of transcatheter mitral valve in valve (MViV) replacement of degenerated bioprosthesis reported early experience in the United States. Given recent increases in transseptal MViV volumes and introduction of the SAPIEN 3 Ultra valve, it is important to determine contemporary outcomes for patients undergoing transseptal SAPIEN 3/SAPIEN 3 Ultra MViV replacement.
Genetic risk factors for COVID-19 and influenza are largely distinct
Authors: Jack A. Kosmicki, Anthony Marcketta, Deepika Sharma, Silvio Alessandro Di Gioia, Samantha Batista, Xiao-Man Yang, Gannie Tzoneva, Hector Martinez, Carlo Sidore, Michael D. Kessler, Julie E. Horowitz, Genevieve H. L. Roberts, Anne E. Justice, Nilanjana Banerjee, Marie V. Coignet, Joseph B. Leader, Danny S. Park, Rouel Lanche, Evan Maxwell, Spencer C. Knight, Xiaodong Bai, Harendra Guturu, Asher Baltzell, Ahna R. Girshick, Shannon R. McCurdy, Raghavendran Partha, Adam J. Mansfield, David A. Turissini, Miao Zhang, Joelle Mbatchou, Kyoko Watanabe, Anurag Verma, Giorgio Sirugo, Kristy Crooks, James R. Cerhan, Silvio Alessandro Di Gioia, Daniel H. Geschwind, Marylyn D. Ritchie, William J. Salerno, Alan R. Shuldiner, Daniel J. Rader, Tooraj Mirshahi, Jonathan Marchini, John D. Overton, David J. Carey, Lukas Habegger, Jeffrey G. Reid, Aris Economides, Christos Kyratsous, Katia Karalis, Alina Baum, Michael N. Cantor, Kristin A. Rand, Eurie L. Hong, Catherine A. Ball, Katherine Siminovitch, Aris Baras, Goncalo R. Abecasis, Manuel A. R. Ferreira
Journal: Nature Genetics (2024)

Abstract Coronavirus disease 2019 (COVID-19) and influenza are respiratory illnesses caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza viruses, respectively. Both diseases share symptoms and clinical risk factors 1 , but the extent to which these conditions have a common genetic etiology is unknown. This is partly because host genetic risk factors are well characterized for COVID-19 but not for influenza, with the largest published genome-wide association studies for these conditions including &gt;2 million individuals 2 and about 1,000 individuals 3–6 , respectively. Shared genetic risk factors could point to targets to prevent or treat both infections. Through a genetic study of 18,334 cases with a positive test for influenza and 276,295 controls, we show that published COVID-19 risk variants are not associated with influenza. Furthermore, we discovered and replicated an association between influenza infection and noncoding variants in B3GALT5 and ST6GAL1 , neither of which was associated with COVID-19. In vitro small interfering RNA knockdown of ST6GAL1—an enzyme that adds sialic acid to the cell surface, which is used for viral entry—reduced influenza infectivity by 57%. These results mirror the observation that variants that downregulate ACE2 , the SARS-CoV-2 receptor, protect against COVID-19 (ref. 7 ). Collectively, these findings highlight downregulation of key cell surface receptors used for viral entry as treatment opportunities to prevent COVID-19 and influenza.
Moving beyond processing- and analysis-related variation in resting-state functional brain imaging
Authors: Xinhui Li, Nathalia Bianchini Esper, Lei Ai, Steve Giavasis, Hecheng Jin, Eric Feczko, Ting Xu, Jon Clucas, Alexandre Franco, Anibal Sólon Heinsfeld, Azeez Adebimpe, Joshua T. Vogelstein, Chao-Gan Yan, Oscar Esteban, Russell A. Poldrack, Cameron Craddock, Damien Fair, Theodore Satterthwaite, Gregory Kiar, Michael P. Milham
Journal: Nature Human Behaviour (2024)
Associations of social determinants of health with life expectancy and future health risks among individuals with type 2 diabetes: two nationwide cohort studies in the UK and USA
Authors: Jiale Zhong, Yanbo Zhang, Kai Zhu, Rui Li, Xiaotao Zhou, Pang Yao, Oscar H Franco, JoAnn E Manson, An Pan, Gang Liu
Journal: The Lancet Healthy Longevity (2024)
<scp>I</scp>g<scp>E</scp> glycosylation and impact on structure and function: A systematic review
Authors: Alexandra J. McCraw, Lais C. G. F. Palhares, Jenifer L. Hendel, Richard A. Gardner, Aida Santaolalla, Silvia Crescioli, James McDonnell, Mieke Van Hemelrijck, Alicia Chenoweth, Daniel I. R. Spencer, Gerd K. Wagner, Sophia N. Karagiannis
Journal: Allergy (2024)

Abstract The impact of human IgE glycosylation on structure, function and disease mechanisms is not fully elucidated, and heterogeneity in different studies renders drawing conclusions challenging. Previous reviews discussed IgE glycosylation focusing on specific topics such as health versus disease, FcεR binding or impact on function. We present the first systematic review of human IgE glycosylation conducted utilizing the PRISMA guidelines. We sought to define the current consensus concerning the roles of glycosylation on structure, biology and disease. Despite diverse analytical methodologies, source, expression systems and the sparsity of data on IgE antibodies from non‐allergic individuals, collectively evidence suggests differential glycosylation profiles, particularly in allergic diseases compared with healthy states, and indicates functional impact, and contributions to IgE‐mediated hypersensitivities and atopic diseases. Beyond allergic diseases, dysregulated terminal glycan structures, including sialic acid, may regulate IgE metabolism. Glycan sites such as N394 may contribute to stabilizing IgE structure, with alterations in these glycans likely influencing both structure and IgE‐FcεR interactions. This systematic review therefore highlights critical IgE glycosylation attributes in health and disease that may be exploitable for therapeutic intervention, and the need for novel analytics to explore pertinent research avenues.
Two‐year post‐treatment outcomes following peanut oral immunotherapy in the Probiotic and Peanut Oral Immunotherapy‐003 Long‐Term (<scp>PPOIT</scp>‐<scp>003LT</scp>) study
Authors: Paxton Loke, Xiaofang Wang, Melanie Lloyd, Sarah E. Ashley, Adriana C. Lozinsky, Michael Gold, Michael D. O'Sullivan, Patrick Quinn, Marnie Robinson, Audrey Dunn Galvin, Francesca Orsini, Mimi L. K. Tang
Journal: Allergy (2024)

Few studies have examined long-term outcomes following oral immunotherapy (OIT); none have examined long-term risks and benefits associated with distinct clinical outcomes (desensitization, remission).
Exemplifying interspecies variation of liposome in vivo fat e by the effects of anti-PEG antibodies
Authors: Ercan Wu, Juan Guan, Yifei Yu, Shiqi Lin, Tianhao Ding, Yuxiu Chu, Feng Pan, Mengyuan Liu, Yang Yang, Zui Zhang, Jian Zhang, Changyou Zhan, Jun Qian
Journal: Acta Pharmaceutica Sinica B (2024)

The different fate of liposomes among species has been discovered and mentioned in many studies, but the underlying mechanisms have not been explored. In the present work, we concentrated on the
Complex genomes of early nucleocytoviruses revealed by ancient origins of viral aminoacyl-tRNA synthetases
Authors: Soichiro Kijima, Hiroyuki Hikida, Tom O Delmont, Morgan Gaïa, Hiroyuki Ogata
Journal: Molecular Biology and Evolution (2024)

Abstract Aminoacyl-tRNA synthetases (aaRSs), also known as tRNA ligases, are essential enzymes in translation. Owing to their functional essentiality, these enzymes are conserved in all domains of life and used as informative markers to trace the evolutionary history of cellular organisms. Unlike cellular organisms, viruses generally lack aaRSs because of their obligate parasitic nature, but several large and giant DNA viruses in the phylum Nucleocytoviricota encode aaRSs in their genomes. The discovery of viral aaRSs led to the idea that the phylogenetic analysis of aaRSs can shed light on ancient viral evolution. However, conflicting results have been reported from previous phylogenetic studies: one posited that nucleocytoviruses recently acquired their aaRSs from their host eukaryotes, while another hypothesized that the viral aaRSs have ancient origins. Here, we investigated 4,168 nucleocytovirus genomes, including metagenome-assembled genomes (MAGs) derived from large-scale metagenomic studies. In total, we identified 780 viral aaRS sequences in 273 viral genomes. We generated and examined phylogenetic trees of these aaRSs with a large set of cellular sequences to trace evolutionary relationships between viral and cellular aaRSs. The analyses suggest that the origins of some viral aaRSs predate the last common eukaryotic ancestor. Inside viral aaRS clades, we identify intricate evolutionary trajectories of viral aaRSs with horizontal transfers, losses, and displacements. Overall, these results suggest that ancestral nucleocytoviruses already developed complex genomes with an expanded set of aaRSs in the proto-eukaryotic era.
Navigating the evolving landscape of atopic dermatitis: Challenges and future opportunities: The 4th Davos declaration
Authors: Claudia Traidl‐Hoffmann, Jamie Afghani, Cezmi A. Akdis, Mübecel Akdis, Handan Aydin, Katja Bärenfaller, Heidrun Behrendt, Thomas Bieber, Paul Bigliardi, Mei Bigliardi‐Qi, Charlotte Menné Bonefeld, Stefanie Bösch, Marie Charlotte Brüggen, Sebastian Diemert, Hans‐Werner Duchna, Martina Fähndrich, Danielle Fehr, Marc Fellmann, Remo Frei, Lena H. Garvey, Raschid Gharbo, Mehmet Gökkaya, Karin Grando, Carole Guillet, Erman Guler, Jan Gutermuth, Nadine Herrmann, Dirk Jan Hijnen, Claudia Hülpüsch, Alan D. Irvine, Erika Jensen‐Jarolim, Heidi H. Kong, Hillel Koren, Claudia C. V. Lang, Roger Lauener, Laura Maintz, Pierre‐Yves Mantel, Emanuel Maverakis, Matthias Möhrenschlager, Svenja Müller, Kari Nadeau, Avidan U. Neumann, Liam O'Mahony, Fahafahantsoa Rapelanoro Rabenja, Harald Renz, Claudio Rhyner, Ernst Rietschel, Johannes Ring, Caroline Roduit, Mari Sasaki, Mirjam Schenk, Jens Schröder, Dagmar Simon, Hans‐Uwe Simon, Milena Sokolowska, Sonja Ständer, Martin Steinhoff, Doris Straub Piccirillo, Alain Taïeb, Roberto Takaoka, Martin Tapparo, Henrique Teixeira, Jacob Pontoppidan Thyssen, Stephan Traidl, Miriam Uhlmann, Willem van de Veen, Marianne van Hage, Christian Virchow, Andreas Wollenberg, Mitamura Yasutaka, Alexander Zink, Peter Schmid‐Grendelmeier
Journal: Allergy (2024)

Abstract The 4th Davos Declaration was developed during the Global Allergy Forum in Davos which aimed to elevate the care of patients with atopic dermatitis (AD) by uniting experts and stakeholders. The forum addressed the high prevalence of AD, with a strategic focus on advancing research, treatment, and management to meet the evolving challenges in the field. This multidisciplinary forum brought together top leaders from research, clinical practice, policy, and patient advocacy to discuss the critical aspects of AD, including neuroimmunology, environmental factors, comorbidities, and breakthroughs in prevention, diagnosis, and treatment. The discussions were geared towards fostering a collaborative approach to integrate these advancements into practical, patient‐centric care. The forum underlined the mounting burden of AD, attributing it to significant environmental and lifestyle changes. It acknowledged the progress in understanding AD and in developing targeted therapies but recognized a gap in translating these innovations into clinical practice. Emphasis was placed on the need for enhanced awareness, education, and stakeholder engagement to address this gap effectively and to consider environmental and lifestyle factors in a comprehensive disease management strategy. The 4th Davos Declaration marks a significant milestone in the journey to improve care for people with AD. By promoting a holistic approach that combines research, education, and clinical application, the Forum sets a roadmap for stakeholders to collaborate to improve patient outcomes in AD, reflecting a commitment to adapt and respond to the dynamic challenges of AD in a changing world.
Advances and Ongoing Challenges in Eosinophilic Gastrointestinal Disorders presented at the CEGIR/TIGERS Symposium at the 2024 American Academy of Allergy, Asthma, &amp; Immunology Meeting
Authors: Benjamin L. Wright, Juan Pablo Abonia, Edsel M. Abud, Seema S. Aceves, Steven J. Ackerman, Melinda Braskett, Joy W. Chang, Mirna Chehade, Gregory M. Constantine, Carla M. Davis, Evan S. Dellon, Alfred D. Doyle, Raquel Durban, David A. Hill, Elizabeth T. Jensen, Anupama Kewalramani, Paneez Khoury, Amy D. Klion, Leah Kottyan, Fei Li Kuang, Emily C. McGowan, Melanie A. Ruffner, Lisa A. Spencer, Jonathan M. Spergel, Amiko M. Uchida, Joshua B. Wechsler, Robert D. Pesek
Journal: Journal of Allergy and Clinical Immunology (2024)
PD-L1 and B7-H3 are Effective Prognostic Factors and Potential Therapeutic Targets for High-Risk Thyroid Cancer
Authors: Xinyi Zhu, Chunfang Hu, Zhe Zhang, Yuelu Zhu, Wenchao Liu, Bo Zheng, Xiaoli Feng, Haizhen Lu
Journal: Endocrine Pathology (2024)